Terapia Génica en Enfermedad de Parkinson
PARKBA SAL
Consiglio Nazionale delle Ricerche
Roma, ItaliaPublications in collaboration with researchers from Consiglio Nazionale delle Ricerche (6)
2018
-
Gene therapy approaches in the non-human primate model of Parkinson’s disease
Journal of Neural Transmission, Vol. 125, Núm. 3, pp. 575-589
2017
-
AAV-PHP.B-Mediated Global-Scale Expression in the Mouse Nervous System Enables GBA1 Gene Therapy for Wide Protection from Synucleinopathy
Molecular Therapy, Vol. 25, Núm. 12, pp. 2727-2742
2014
-
L-DOPA disrupts adenosine A2A-cannabinoid CB1-dopamine D2 receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: Biochemical and behavioral studies
Experimental Neurology, Vol. 253, pp. 180-191
-
L-DOPA-treatment in primates disrupts the expression of A2A adenosine-CB1 cannabinoid-D2 dopamine receptor heteromers in the caudate nucleus
Neuropharmacology, Vol. 79, pp. 90-100
-
Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease
Journal of Neuropathology and Experimental Neurology, Vol. 73, Núm. 5, pp. 414-424
2011
-
Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease
Pharmacology and Therapeutics, Vol. 132, Núm. 3, pp. 280-299